Your browser doesn't support javascript.
loading
Can we trust the prediction model? Demonstrating the importance of external validation by investigating the COVID-19 Vulnerability (C-19) Index across an international network of observational healthcare datasets
Jenna M Reps; Chungsoo Kim; Ross D. Williams; Aniek F Markus; Cynthia Yang; Talita Duarte Salles; Thomas Falconer; Jitendra Jonnagaddala; Andrew Williams; Sergio Fernandez-Bertolin; Scott L DuVall; Kristin Kostka; Gowtham Rao; Azza Shoaibi; Anna Ostropolets; Matthew E Spotnitz; Lin Zhang; Paula Casajust; Ewout Steyerberg; Fredrik Nyberg; Benjamin Skov Kaas-Hansen; Young Hwa Choi; Daniel Morales; Siaw-Teng Liaw; Maria Tereza Fernandes Abrahao; Carlos Areia; Michael E Matheny; Maria Aragon; Rae Woong Park; George Hripcsak; Christian G Reich; Marc A Suchard; Seng Chan You; Patrick B Ryan; Daniel Prieto-Alhambra; Peter R Rijnbeek.
Afiliación
  • Jenna M Reps; Janssen R&D
  • Chungsoo Kim; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea
  • Ross D. Williams; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Aniek F Markus; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Cynthia Yang; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Talita Duarte Salles; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • Thomas Falconer; Department of Biomedical Informatics, Columbia University, New York, NY
  • Jitendra Jonnagaddala; School of Public Health and Community Medicine, UNSW Sydney
  • Andrew Williams; Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, 02111, USA
  • Sergio Fernandez-Bertolin; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • Scott L DuVall; Department of Veterans Affairs, USA; University of Utah, USA
  • Kristin Kostka; Real World Solutions, IQVIA, Cambridge, MA, United States
  • Gowtham Rao; Janssen Research & Development, Titusville, NJ, USA
  • Azza Shoaibi; Janssen Research & Development, Titusville, NJ, USA
  • Anna Ostropolets; Department of Biomedical Informatics, Columbia University, New York, NY
  • Matthew E Spotnitz; Department of Biomedical Informatics, Columbia University, New York, NY
  • Lin Zhang; School of Public Health, Peking Union Medical College, Beijing, China
  • Paula Casajust; Department of Real-World Evidence, Trial Form Support, Barcelona, Spain
  • Ewout Steyerberg; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Fredrik Nyberg; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg, Sweden
  • Benjamin Skov Kaas-Hansen; Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark
  • Young Hwa Choi; Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea
  • Daniel Morales; ivision of Population Health and Genomics, University of Dundee, UK
  • Siaw-Teng Liaw; School of Public Health and Community Medicine, UNSW Sydney
  • Maria Tereza Fernandes Abrahao; Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil
  • Carlos Areia; Nuffield Department of Clinical Neurosciences, University of Oxford
  • Michael E Matheny; Department of Veterans Affairs, USA; Vanderbilt University, USA
  • Maria Aragon; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • Rae Woong Park; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea
  • George Hripcsak; Department of Biomedical Informatics, Columbia University, New York, NY
  • Christian G Reich; Real World Solutions, IQVIA, Cambridge, MA, United States
  • Marc A Suchard; Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Seng Chan You; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea
  • Patrick B Ryan; Janssen Research & Development, Titusville, NJ, USA
  • Daniel Prieto-Alhambra; Centre for Statistics in Medicine, NDORMS, University of Oxford
  • Peter R Rijnbeek; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
Preprint en Inglés | medRxiv | ID: ppmedrxiv-20130328
ABSTRACT
BackgroundSARS-CoV-2 is straining healthcare systems globally. The burden on hospitals during the pandemic could be reduced by implementing prediction models that can discriminate between patients requiring hospitalization and those who do not. The COVID-19 vulnerability (C-19) index, a model that predicts which patients will be admitted to hospital for treatment of pneumonia or pneumonia proxies, has been developed and proposed as a valuable tool for decision making during the pandemic. However, the model is at high risk of bias according to the Prediction model Risk Of Bias ASsessment Tool and has not been externally validated. MethodsWe followed the OHDSI framework for external validation to assess the reliability of the C-19 model. We evaluated the model on two different target populations i) 41,381 patients that have SARS-CoV-2 at an outpatient or emergency room visit and ii) 9,429,285 patients that have influenza or related symptoms during an outpatient or emergency room visit, to predict their risk of hospitalization with pneumonia during the following 0 to 30 days. In total we validated the model across a network of 14 databases spanning the US, Europe, Australia and Asia. FindingsThe internal validation performance of the C-19 index was a c-statistic of 0.73 and calibration was not reported by the authors. When we externally validated it by transporting it to SARS-CoV-2 data the model obtained c-statistics of 0.36, 0.53 (0.473-0.584) and 0.56 (0.488-0.636) on Spanish, US and South Korean datasets respectively. The calibration was poor with the model under-estimating risk. When validated on 12 datasets containing influenza patients across the OHDSI network the c-statistics ranged between 0.40-0.68. InterpretationThe results show that the discriminative performance of the C-19 model is low for influenza cohorts, and even worse amongst COVID-19 patients in the US, Spain and South Korea. These results suggest that C-19 should not be used to aid decision making during the COVID-19 pandemic. Our findings highlight the importance of performing external validation across a range of settings, especially when a prediction model is being extrapolated to a different population. In the field of prediction, extensive validation is required to create appropriate trust in a model.
Licencia
cc_by_nc_nd
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Cohort_studies / Experimental_studies / Estudio observacional / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Cohort_studies / Experimental_studies / Estudio observacional / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint
...